QL1706 (Iparomlimab/Tuvonralimab)

DRUG3 trials

Sponsors

The First Affiliated Hospital with Nanjing Medical University, Fujian Medical University, Fudan University

Conditions

Biliary Tract Cancer (BTC)Colon CancerGastric Cancer Stage IIISynchronous Liver Metastases

Phase 2

QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer

Not yet recruitingNCT07315035

The First Affiliated Hospital with Nanjing Medical UniversityGastric Cancer Stage III

Start: 2026-01-01End: 2030-12-31Target: 74Updated: 2026-01-02

QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study

Not yet recruitingNCT07649473

Fujian Medical UniversityColon Cancer, Synchronous Liver Metastases

Start: 2026-08-15End: 2033-12-31Target: 30Updated: 2026-06-16

Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.

Not yet recruitingNCT07829874

Fudan UniversityBiliary Tract Cancer (BTC)

Start: 2026-09-20End: 2029-09-20Target: 180Updated: 2026-09-21